Influence of Periodontitis and Coronary Heart Disease on Galectin-3
Influence of Periodontitis and Coronary Heart Disease on Galectin-3 in Serum and Saliva
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Messina, Italy, 98100
- University of Messina
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Presence of at least 16 teeth
CP with a minimum of 40% of sites with a clinical attachment level (CAL)
≥2mm and probing depth (PD) ≥4mm;
- Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
- Presence of ≥40% sites with bleeding on probing (BOP)
Exclusion Criteria:
- Intake of contraceptives
- Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
- Status of pregnancy or lactation
- Previous history of excessive drinking
- Allergy to local anaesthetic
- Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Control
Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
|
Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
|
|
Periodontitis
Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
|
Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
|
|
Coronary heart disease
Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
|
Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
|
|
Coronary heart disease + periodontitis
Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
|
Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of Clinical Attachment Level (mm)
Time Frame: 1-year
|
Measurment of changes in Clinical Attachment Level
|
1-year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 18-16-2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontal Diseases
-
NCT07446127RecruitingPeriodontal Disease | Periodontal Attachment Loss | Periodontal Pockets
-
NCT07254117RecruitingPeriodontitis | Periodontal Diseases | Periodontal Bone Loss | Periodontal Disease | Periodontal Regeneration | Periodontal Healing | Periodontal Granulation Tissue | Vertical Periodontal Bone Defects
-
NCT07468929Not yet recruitingPeriodontal Disease | Periodontal Surgery
-
NCT05858411RecruitingPeriodontal Diseases | Intrabony Periodontal Defect | Periodontal Attachment Loss | Pocket, Periodontal
-
NCT07146776RecruitingPeriodontitis | Periodontal Diseases | Periodontal Bone Loss | Intrabony Periodontal Defect | Periodontal Defect
-
NCT07520968Active, not recruitingPeriodontal Disease | Periodontal Disease, AVDC Stage 3 | Periodontal Disease Stage 2
-
NCT07581613Not yet recruitingPeriodontal Disease | Intrabony Periodontal Defects
-
NCT07358104Active, not recruitingPeriodontal Diseases | Periodontal Attachment Loss
-
NCT06404190CompletedPeriodontitis | Periodontal Attachment Loss | Periodontal Inflammation | Pocket, Periodontal
-
NCT05233501CompletedPeriodontal Diseases | Periodontal Attachment Loss | Periodontal Inflammation | Periodontal Disease, AVDC Stage 3 | Periodontal Disease, AVDC Stage 4
Clinical Trials on Observation of serum and salivary Galectin-3 levels
-
NCT04450810CompletedPeriodontal Diseases | Metabolic Disease
-
NCT04335344CompletedPeriodontal Diseases | Metabolic Disturbance
-
NCT06005389CompletedHuman Papillomavirus Infection
-
NCT04417322CompletedPeriodontal Diseases
-
NCT05449821RecruitingObesity | Diabetes Mellitus | Periodontitis
-
NCT03020108CompletedEndometriosis | Apoptotic Pathway Deregulation
-
NCT05992727Not yet recruitingGalectin-3 and Pemphigus
-
NCT06986044CompletedPeriodontal Health | Periodontitis Stage III
-
NCT05213325RecruitingAcute Gastroenteritis | Acute Diarrhea